Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Amelie M.L. Delcourt"'
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer
Autor:
Preston D. Crowell, Jenna M. Giafaglione, Anthony E. Jones, Nicholas M. Nunley, Takao Hashimoto, Amelie M.L. Delcourt, Anton Petcherski, Raag Agrawal, Matthew J. Bernard, Johnny A. Diaz, Kylie Y. Heering, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Nora M. Navone, Huihui Ye, Amina Zoubeidi, Heather R. Christofk, Matthew B. Rettig, Robert E. Reiter, Michael C. Haffner, Paul C. Boutros, Orian S. Shirihai, Ajit S. Divakaruni, Andrew S. Goldstein
Publikováno v:
Cell Reports, Vol 42, Iss 10, Pp 113221- (2023)
Summary: Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor
Externí odkaz:
https://doaj.org/article/918185a092bc44e997b51df4ec5e68c1
Autor:
Preston D. Crowell, Jenna M. Giafaglione, Anthony E. Jones, Nicholas M. Nunley, Takao Hashimoto, Amelie M.L. Delcourt, Anton Petcherski, Matthew J. Bernard, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Xiangnan Guan, Nora M. Navone, Joshi J. Alumkal, Michael C. Haffner, Huihui Ye, Amina Zoubeidi, Heather R. Christofk, Orian S. Shirihai, Ajit S. Divakaruni, Andrew S. Goldstein
Prostate cancer cells that survive clinical androgen receptor (AR) blockade mediate disease progression and lethality. Reprogrammed metabolic signaling is one mechanism by which tumor cells can survive treatment. However, how AR inhibition reprograms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0a0067d9d5b6a18243deae560dd4938
https://doi.org/10.1101/2022.05.31.494200
https://doi.org/10.1101/2022.05.31.494200